Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1992 2
1993 2
1994 1
1995 2
1997 1
1998 3
1999 2
2000 1
2001 2
2002 1
2003 2
2004 5
2005 2
2006 3
2007 5
2008 7
2009 6
2010 5
2011 12
2012 9
2013 11
2014 13
2015 14
2016 25
2017 19
2018 21
2019 16
2020 22
2021 21
2022 26
2023 20
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Solomon BJ, et al. N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. N Engl J Med. 2014. PMID: 25470694 Free article. Clinical Trial.
[Groundbreaking basic research].
Helland Å. Helland Å. Tidsskr Nor Laegeforen. 2018 Dec 10;138(20). doi: 10.4045/tidsskr.18.0802. Print 2018 Dec 11. Tidsskr Nor Laegeforen. 2018. PMID: 30539600 Free article. Norwegian. No abstract available.
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Among authors: helland a. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.
Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Stankovic B, et al. Among authors: helland a. Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018. Front Immunol. 2019. PMID: 30774636 Free PMC article.
Hever kvaliteten på behandling av kreft.
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.
Lehtiö J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, Umer HM, Mermelekas G, Pirmoradian M, Jönsson M, Brunnström H, Brustugun OT, Purohit KP, Cunningham R, Foroughi Asl H, Isaksson S, Arbajian E, Aine M, Karlsson A, Kotevska M, Gram Hansen C, Drageset Haakensen V, Helland Å, Tamborero D, Johansson HJ, Branca RM, Planck M, Staaf J, Orre LM. Lehtiö J, et al. Among authors: helland a. Nat Cancer. 2021 Nov;2(11):1224-1242. doi: 10.1038/s43018-021-00259-9. Epub 2021 Nov 22. Nat Cancer. 2021. PMID: 34870237 Free PMC article.
Nye anbefalinger ved serumkonsentrasjonsmålinger av sentralstimulerende legemidler.
Frost J, Bernard JP, Dietrichs ES, Kjeldstadli K, Riedel B, Skråstad RB, Vevelstad M, Helland A. Frost J, et al. Among authors: helland a. Tidsskr Nor Laegeforen. 2019 Sep 23;139(13). doi: 10.4045/tidsskr.19.0385. Print 2019 Sep 24. Tidsskr Nor Laegeforen. 2019. PMID: 31556515 Free article. Norwegian. No abstract available.
272 results